$9.55
-0.45[-4.50%]
At close: Apr 23
$9.55
0[0.00%]
After Hours: 5:27PM EDT
Centessa Pharmaceuticals
(NASDAQ:CNTA)Centessa Pharmaceuticals Stock (NASDAQ:CNTA), Analyst Ratings, Price Targets, Predictions
Centessa Pharmaceuticals PLC has a consensus price target of $11.22, established from looking at the 24 latest analyst ratings. The last 3 analyst ratings were released from BMO Capital, Jefferies, and Morgan Stanley on April 1, 2024, November 15, 2023, and October 26, 2023. With an average price target of $11.33 between BMO Capital, Jefferies, and Morgan Stanley, there's an implied 18.67% upside for Centessa Pharmaceuticals PLC from these 3 analyst ratings.
Analyst Firms Making Recommendations1
BMO Capital
Jefferies
Morgan Stanley
SVB Securities
Guggenheim
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Centessa Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/01/2024 | CNTA | Buy Now | Centessa Pharmaceuticals | $9.55 | 57.07% | BMO Capital | Kostas Biliouris | $15 → $15 | Maintains | Outperform | Get Alert |
| 11/15/2023 | CNTA | Buy Now | Centessa Pharmaceuticals | $9.55 | 15.18% | Jefferies | Kelly Shi | $4 → $11 | Upgrade | Hold → Buy | Get Alert |
| 10/26/2023 | CNTA | Buy Now | Centessa Pharmaceuticals | $9.55 | -16.23% | Morgan Stanley | Matthew Harrison | $4 → $8 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 08/15/2023 | CNTA | Buy Now | Centessa Pharmaceuticals | $9.55 | 15.18% | SVB Securities | David Risinger | $6 → $11 | Maintains | Outperform | Get Alert |
| 08/15/2023 | CNTA | Buy Now | Centessa Pharmaceuticals | $9.55 | 4.71% | Guggenheim | Debjit Chattopadhyay | $9 → $10 | Maintains | Buy | Get Alert |
| 08/15/2023 | CNTA | Buy Now | Centessa Pharmaceuticals | $9.55 | -47.64% | Goldman Sachs | Salveen Richter | $4.5 → $5 | Maintains | Neutral | Get Alert |
| 07/25/2023 | CNTA | Buy Now | Centessa Pharmaceuticals | $9.55 | 57.07% | BMO Capital | Kostas Biliouris | $11 → $15 | Maintains | Outperform | Get Alert |
| 06/21/2023 | CNTA | Buy Now | Centessa Pharmaceuticals | $9.55 | — | Evercore ISI Group | Umer Raffat | — | Initiates | → Outperform | Get Alert |
| 06/12/2023 | CNTA | Buy Now | Centessa Pharmaceuticals | $9.55 | -5.76% | Guggenheim | Debjit Chattopadhyay | → $9 | Initiates | → Buy | Get Alert |
| 05/15/2023 | CNTA | Buy Now | Centessa Pharmaceuticals | $9.55 | -52.88% | Goldman Sachs | Salveen Richter | $4 → $4.5 | Maintains | Neutral | Get Alert |
| 03/17/2023 | CNTA | Buy Now | Centessa Pharmaceuticals | $9.55 | -37.17% | SVB Leerink | David Risinger | → $6 | Initiates | → Outperform | Get Alert |
| 01/24/2023 | CNTA | Buy Now | Centessa Pharmaceuticals | $9.55 | -58.12% | Morgan Stanley | Matthew Harrison | $5 → $4 | Maintains | Underweight | Get Alert |
| 08/12/2022 | CNTA | Buy Now | Centessa Pharmaceuticals | $9.55 | -47.64% | Morgan Stanley | Matthew Harrison | $10 → $5 | Downgrade | Overweight → Underweight | Get Alert |
| 08/11/2022 | CNTA | Buy Now | Centessa Pharmaceuticals | $9.55 | 15.18% | BMO Capital | Kostas Biliouris | $19 → $11 | Maintains | Outperform | Get Alert |
| 08/11/2022 | CNTA | Buy Now | Centessa Pharmaceuticals | $9.55 | -58.12% | Goldman Sachs | Salveen Richter | $5 → $4 | Maintains | Neutral | Get Alert |
| 07/15/2022 | CNTA | Buy Now | Centessa Pharmaceuticals | $9.55 | 4.71% | Morgan Stanley | Matthew Harrison | $15 → $10 | Maintains | Overweight | Get Alert |
| 06/17/2022 | CNTA | Buy Now | Centessa Pharmaceuticals | $9.55 | 98.95% | BMO Capital | Kostas Biliouris | → $19 | Initiates | → Outperform | Get Alert |
| 05/24/2022 | CNTA | Buy Now | Centessa Pharmaceuticals | $9.55 | 57.07% | Morgan Stanley | Matthew Harrison | $19 → $15 | Maintains | Overweight | Get Alert |
| 05/24/2022 | CNTA | Buy Now | Centessa Pharmaceuticals | $9.55 | -16.23% | Goldman Sachs | Salveen Richter | $12 → $8 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Centessa Pharmaceuticals (CNTA)?
The latest price target for Centessa Pharmaceuticals (NASDAQ: CNTA) was reported by BMO Capital on April 1, 2024. The analyst firm set a price target for $15.00 expecting CNTA to rise to within 12 months (a possible 57.07% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Centessa Pharmaceuticals (CNTA)?
The latest analyst rating for Centessa Pharmaceuticals (NASDAQ: CNTA) was provided by BMO Capital, and Centessa Pharmaceuticals maintained their outperform rating.
When was the last upgrade for Centessa Pharmaceuticals (CNTA)?
The last upgrade for Centessa Pharmaceuticals PLC happened on November 15, 2023 when Jefferies raised their price target to $11. Jefferies previously had a hold for Centessa Pharmaceuticals PLC.
When was the last downgrade for Centessa Pharmaceuticals (CNTA)?
The last downgrade for Centessa Pharmaceuticals PLC happened on August 12, 2022 when Morgan Stanley changed their price target from $10 to $5 for Centessa Pharmaceuticals PLC.
When is the next analyst rating going to be posted or updated for Centessa Pharmaceuticals (CNTA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Centessa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Centessa Pharmaceuticals was filed on April 1, 2024 so you should expect the next rating to be made available sometime around April 1, 2025.
Is the Analyst Rating Centessa Pharmaceuticals (CNTA) correct?
While ratings are subjective and will change, the latest Centessa Pharmaceuticals (CNTA) rating was a maintained with a price target of $15.00 to $15.00. The current price Centessa Pharmaceuticals (CNTA) is trading at is $9.55, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.